SAN MATEO, CA — April 27, 2007 — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the following abstracts have been accepted for the Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois on June 1-5, 2007:
ZADAXIN® (thymalfasin, thymosin alpha 1) Poster Presentation
A large first-line, randomized, dose-finding, phase II study on Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with or without Interferon alpha (IFN?) vs DTIC plus IFN? in stage IV melanoma. Tumor response and survival results
(ASCO abstract number: 31541)
SCV-07 Abstract Proceedings
Effect of the Immune Modulating Peptide, SCV-07, in the Murine B16 Melanoma Model
(ASCO abstract number: 35151)
For further information about this conference, please visit www.asco.org.
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC BeadTM, currently pending Chinese regulatory approval for the treatment of liver cancer. For the U.S. market, SciClone's clinical-stage drug development candidates are SCV-07 for the treatment of viral infectious diseases and RP101 for the treatment of pancreatic cancer. For more information about SciClone, visit www.sciclone.com.
The information in the abstracts may contain forward-looking statements including our expectations and beliefs regarding progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended," “suggested” and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including the progress or failure of clinical trials, unanticipated delays or additional expenses incurred during our clinical trials, delays in analyzing and synthesizing data obtained from clinical trials and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.
Richard A. Waldron
Executive Vice President and Chief Financial Officer
SciClone Pharmaceuticals, Inc.